A nurse is caring for a client who has prostate cancer. The nurse should expect the provider to prescribe which of the following medications for this client?

Rationale: A. This is a selective estrogen receptor modulator (SERM) used primarily in the treatment and prevention of estrogen receptor–positive breast cancer in women. It is not used for prostate cancer, which is an androgen-dependent tumor. B. This medication is a 5-alpha reductase inhibitor used for benign prostatic hyperplasia (BPH) and male pattern baldness. While it reduces prostate size and androgen levels locally, it is not a standard treatment for prostate cancer because it does not adequately suppress systemic testosterone levels. C. This is an alkylating chemotherapeutic agent used for a variety of cancers (e.g., lymphomas, breast cancer) and autoimmune disorders, but it is not a first-line treatment for prostate cancer. D. Leuprolide is a gonadotropin-releasing hormone (GnRH) agonist that initially increases luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels but eventually suppresses pituitary secretion of these hormones. The result is decreased testosterone production by the testes, which helps slow the growth of androgen-dependent prostate cancer cells.